November 10, 2023 – Page 6

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023

Written by Customer Service on November 10, 2023. Posted in Public Companies.

Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due to NASH/MASH 22% and 10% of patients with more advanced cirrhosis in the 50mg and 28mg dose groups, respectively, had at least a one-stage improvement in fibrosis without worsening of NASH, over 7 and 3 times, respectively, the placebo rate of 3% Additional analyses from the HARMONY and SYMMETRY studies indicate that histological improvements associated with EFX do not appear to be attributable to concomitant use of GLP-1 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked...

Koil Energy Solutions Announces Updated Date and Time for Its Third Quarter 2023 Results Conference Call

Written by Customer Service on November 10, 2023. Posted in Public Companies.

HOUSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) — Koil Energy Solutions, Inc. (OTCQB: KLNG) has rescheduled its investor conference call to discuss its third quarter 2023 results to Monday, November 13, 2023 at 10:00 am Eastern Time (call details below). Call Dial-in: Toll Free: 1-833-630-1956 Toll/International: 1-412-317-1837 Please ask to join the Koil Energy Solutions call. Webcast URL: https://edge.media-server.com/mmc/p/24vftbx6 A replay will be available through November 27, 2023 on our website, www.koilenergy.com, under the “Investors” section. About Koil Energy, Inc. (www.koilenergy.com) Koil Energy Solutions is a leading energy services company offering subsea equipment and support services to the world’s energy and offshore industries. We provide innovative solutions to complex customer challenges presented...

Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval

Written by Customer Service on November 10, 2023. Posted in Public Companies.

Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a Day 180 Second List of Outstanding Issues (LoOI) from the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) regarding its Marketing Authorisation Application (MAA) for leniolisib for adult and pediatric patients 12 years of age and older with APDS, a rare primary immunodeficiency. Based on the timetable included in the CHMP Day 180 Second LoOI, and considering the CHMP’s decision to reschedule the Ad-Hoc Expert Group (AEG) meeting to the end of November, Pharming now expects the CHMP to issue its opinion on the leniolisib MAA in the first quarter of 2024. Pharming now intends to file an MAA with the U.K. Medicines and Healthcare products Regulatory...

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat

Written by Customer Service on November 10, 2023. Posted in Public Companies.

Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023 EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it expects to release additional efficacy data from the Phase 2 ALTITUDE-NASH clinical trial of its lead drug, rencofilstat, after market close on Monday, November 13, 2023. The data release will follow a late-breaker poster presentation by Hepion’s Senior Vice President, Clinical Pharmacology, Patrick Mayo, PhD, at the Liver Meeting® 2023, to be hosted by the American Association...

Century Announces Filing of Second Quarter Financial Results and Management Discussion and Analysis for Six Months Ended September 30, 2023

Written by Customer Service on November 10, 2023. Posted in Earnings Releases And Operating Results.

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION INTHE UNITED STATES OR TO U.S. NEWS AGENCIES HONG KONG, Nov. 10, 2023 (GLOBE NEWSWIRE) — Century Global Commodities Corporation (“Century” or the “Company”) (TSX: CNT) is pleased to announce that it has filed its condensed consolidated interim financial statements for the second fiscal quarter ended September 30, 2023 and the related management discussion and analysis (“MD&A”). Copies of these documents are available under Century’s SEDAR+ profile at www.sedarplus.ca and will also be posted on Century’s website at www.centuryglobal.ca. As of September 30, 2023, the Company had net working capital* of $7.0 million, consisting of unrestricted free cash, bank deposits and marketable securities totaling $5.6 million, together with accounts receivables and other current assets of $4.0 million,...

Inuvo Reports Record Quarterly Revenue of $24.6 Million, a 44% Year-Over-Year Increase for the Third Quarter of 2023

Written by Customer Service on November 10, 2023. Posted in Earnings Releases And Operating Results.

Reports positive free cash flow and adjusted EBITDA Management to host conference call at 11:00 AM ET today, Friday, November 10, 2023 LITTLE ROCK, Ark., Nov. 10, 2023 (GLOBE NEWSWIRE) — Inuvo, Inc. (NYSE American: INUV), a leading provider of marketing technology, powered by artificial intelligence (AI) that serves brands and agencies, today provided a business update, and announced its financial results for the third quarter ended September 30, 2023. Recent Highlights: Added a dozen new clients across non-profit sector, entertainment, oil & gas, consulting and retail industries Released version 2.0 of the AI-powered Audience Discovery Portal Announced that by using its IntentKey solution, advertisers can reach their desired audiences on Safari browser, despite new privacy restrictions Significantly enhanced IntentKey’s...

The Real Good Food Company Reports Third Quarter 2023 Financial Results

Written by Customer Service on November 10, 2023. Posted in Earnings Releases And Operating Results.

CHERRY HILL, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) — The Real Good Food Company, Inc. (NASDAQ: RGF) (“Real Good Foods” or the “Company”), a leading health and wellness frozen and refrigerated foods company, today reported financial results for its third quarter ended September 30, 2023. Management Commentary “The third quarter was highlighted by significant acceleration in top-line growth and margin expansion,” said Bryan Freeman, Executive Chairman. “Although we had some operational challenges in the quarter that led to us under-shipping demand, I am encouraged by the strength of our brand as evidenced by the growth in our household penetration and consumption. I have confidence in the ability of our dedicated team to continue to deliver upon our brand promise to consumers and unlock significant value for all our stakeholders...

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

Written by Customer Service on November 10, 2023. Posted in Public Companies.

WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that two posters recapping the positive data from pharmacokinetic (PK) and pharmacodynamic (PD) pre-clinical and clinical studies of Anaphylm™ (epinephrine) Sublingual Film will be presented at the American College of Allergy Asthma and Immunology (ACAAI) annual meeting, which will be held from November 9-13 in Anaheim, California. “We are thrilled to have a significant presence at ACAAI this year and are excited to share the positive results from our completed Anaphylm pharmacokinetic and pharmacodynamic studies with leaders in the...

Optimi Health Resolves Dispute

Written by Customer Service on November 10, 2023. Posted in Public Companies.

VANCOUVER, British Columbia, Nov. 10, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) is pleased to announce the successful resolution of a dispute that arose in connection with a termination notice related to a supply agreement (“the Supply Agreement”) signed with a private entity on May 4, 2023. Optimi is pleased to confirm that the dispute has been amicably resolved and the Supply Agreement has been terminated through a negotiated settlement. This resolution underscores Optimi’s commitment to maintaining positive relationships with its partners while upholding its business integrity. The Company remains dedicated to delivering on its mission of providing high-quality drug candidates and services in the psychedelics sector. For...

REMINDER: Saputo Inc.: Fiscal 2024 Second Quarter Results

Written by Customer Service on November 10, 2023. Posted in Public Companies.

MONTRÉAL, Nov. 10, 2023 (GLOBE NEWSWIRE) — Saputo Inc. (TSX:SAP) – Saputo will release its fiscal 2024 second quarter financial results on Thursday, November 9, 2023. A press release will be issued after markets close, and a conference call is scheduled on Friday, November 10, 2023, at 8:30 a.m. (Eastern Time) to discuss the Company’s results. The speakers will be Mr. Lino A. Saputo, Chair of the Board, President and CEO and Mr. Maxime Therrien, Chief Financial Officer and Secretary. To participate: Webcast: https://www.gowebcasting.com/12926Presentation slides will be included in the webcast and can also be accessed in the “Investors” section of Saputo’s website (www.saputo.com), under “Calendar of Events”. Conference line: 1-800-940-2599Please dial-in five minutes prior to the start time. Replay of the conference call and...

Day: November 10, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice